Simvastatin in severe primary hypercholesterolemia: Efficacy, safety, and tolerability in 595 patients over 18 weeks-Reference-Cited by-同舟云学术

Simvastatin in severe primary hypercholesterolemia: Efficacy, safety, and tolerability in 595 patients over 18 weeks

Published:1993-04 Issue:4 Volume:16 Page:317-322
ISSN:0160-9289
Container-title:Clinical Cardiology
language:en
Short-container-title:Clin Cardiol

Author:

Simons Leon A.

Publisher

Wiley

Subject

Cardiology and Cardiovascular Medicine,General Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/clc.4960160406/fullpdf

Reference28 articles.

1. ML-236A, ML-236B and ML-236C, new inhibitors of cholesterologenesis produced by Penicillium citrinum;Endo;J Antibiot (Tokyo),1976

2. Mevinolin: A highly potent competitive inhibitor of hydroxymethylglutaryl coenzyme A reductase and a cholesterol-lowering agent;Alberts;Proc Natl Acad Sci (USA),1980

3. HMG-CoA reductase inhibitors for treatment of hypercholesterolemia;Grundy;N Engl J Med,1988

4. Mevinolin and colestipol stimulate receptor-mediated clearance of low density lipoproteins from plasma in familial hypercholesterolemia heterozygotes;Bilheimer;Proc Natl Acad Sci (USA),1983

5. Effects of simvastatin on plasma lipoproteins and cholesterol homeostasis in patients with heterozygous familial hypercholesterolemia;Hagemenas;Eur J Clin Invest,1990

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Leptin receptor polymorphism is associated with serum lipid levels and impairment of cholesterol lowering effect by simvastatin in Japanese men;Diabetes Research and Clinical Practice;2003-12

2. Atrial fibrillation induced by simvastatin treatment in a 61-year-old man;Heart and Vessels;2003-07-01

3. A placebo-controlled, double-blind, randomised trial of magnesium-pyridoxal-5'-phosphate-glutamate for hypercholesterolaemia and other clinical–chemical risk factors of cardiovascular disease in a primary care setting;European Journal of Clinical Pharmacology;2001-02-16

4. A population-based treat-to-target pharmacoeconomic analysis of HMG-CoA reductase inhibitors in hypercholesterolemia;Clinical Therapeutics;1999-03

5. An Overview of the Clinical Safety Profile of Atorvastatin (Lipitor), a New HMG-CoA Reductase Inhibitor;Archives of Internal Medicine;1998-03-23